Active, not recruitingPhase 2NCT03541902
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Matthew T CampbellM.D. Anderson Cancer Center
- Intervention
- Cabozantinib(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2027
Study locations (3)
- M D Anderson Cancer Center, Houston, Texas, United States
- MD Anderson Regional Care Center-Katy, Houston, Texas, United States
- MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
Collaborators
Exelixis · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03541902 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)